-
Mashup Score: 0An Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry Disease - 4 year(s) ago
Fabry disease (FD) is an X‐linked lysosomal storage disorder caused by pathogenic variants in the α‐galactosidase A gene (GLA) that leads to reduced or undetectable α‐galactosidase A (AGAL‐A) enzyme …
Source: Wiley Online LibraryCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Treatment switch in Fabry disease- a matter of dose? - 4 year(s) ago
Background Patients with Fabry disease (FD) on reduced dose of agalsidase-beta or after switch to agalsidase-alfa show a decline in chronic kidney disease epidemiology collaboration-based estimated glomerular filtration rate (eGFR) and a worsened plasma lyso-Gb3 decrease. Hence, the most effective dose is still a matter of debate. Methods In this prospective observational study, we assessed…
Source: Journal of Medical GeneticsCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Treatment switch in Fabry disease- a matter of dose? https://t.co/kM1b7r5JPC #fabry #fabrydisease #genetics #medicalgenetics
-
Everything you ever wanted to know about #Fabry Disease! Check out the Expert Consensus Document in #EJHF https://t.co/DS2DXvotcm #cardiotwitter @MarcoMetra @HFA_President @kevin_damman https://t.co/5tLKRuB3ii